OSE-172, a new generation immune checkpoint inhibitor, acting on suppressor immune cell targets

OSE-172, a global license and collaboration agreement with Boehringer Ingelheim to jointly develop the product for the treatment of advanced solid tumors

  • Boehringer Ingelheim has acquired the global rights to develop, register and commercialize OSE-172 (View the press release).
  • OSE-172, an anti-SIRP-alpha monoclonal antibody, is currently in late stage preclinical development with potential in various cancers.

New collaboration and license agreements on other programs will be considered with industry partners involved in activation or regulation immunology, and in therapeutic combinations of high clinical interest.